
Recursion nabs $239M and an up to $1B partnership with Bayer as AI race heats up
Some biotechs struggle for cash. Recursion, lately, seems to be swimming in it.
Today, having already raised over $180 million in the last two years, the Salt Lake City-based AI drug developer announced a $239 million Series D. That’s more than any US or European biotech has raised in a round this year and more than all but two biotechs raised last year. (Mabwell, a Shanghai-based antibody developer, raised $278 million in a Series A in April.)
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.